Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMaud D’AveniJBJacques‐Olivier BayCBClaude-Éric Bulabois

Discussion

Loading...

Member takes

Overview

Analysis reveals post-transplant cyclophosphamide may reduce severe GVHD in AML, indicating improved outcomes over ATG.

Key Points

  • Cumulative incidence of grade III-IV aGVHD was significantly lower with PTCy compared to ATG, showing a potential benefit for patient outcomes.
  • At two years, the incidence of mod-ext cGVHD was lower in PTCy groups, supporting the hypothesis of superior risk management.
  • Relying on national registry data, this observational analysis addressed GVHD prophylaxis effectiveness across diverse transplant conditions.
  • These findings suggest a shift towards incorporating PTCy in standard practices for GVHD prophylaxis in AML transplantations.

Cite This Study

D’Aveni et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1efhttps://doi.org/10.1182/blood-2025-2450
View Full Paper
Ask AI
Bookmark
Share